Editas Medicine (EDIT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$47.0M

Revenue (quarter)

$11.9M

Revenue growth (year over year)

+232.31%

Gross profit (trailing twelve months)

$47.0M

Gross margin

100.00%

Net income (trailing twelve months)

−$73.9M

Net income (quarter)

−$18.2M

Net income growth (year over year)

+65.76%

Net margin

−157.32%

Return on equity

−118.82%

EPS (trailing twelve months)

−$0.66

Book value per share

$0.69

P/E (trailing twelve months)

—

Price to book

3.74

Debt to assets

55.65%

Payout ratio

—

Dividend yield

—

Company profile

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

• Is Editas Medicine (EDIT) profitable?

  No. Editas Medicine reported a net loss of $73.9M over the trailing twelve months.

• How much revenue does Editas Medicine (EDIT) make?

  Editas Medicine generated $47.0M in revenue over the trailing twelve months, up 232.31% year over year.

• How do I buy stock in Editas Medicine (EDIT)?

  EDIT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.